387 related articles for article (PubMed ID: 25326839)
1. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
Fernández-García JC; Colomo N; Tinahones FJ
Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839
[TBL] [Abstract][Full Text] [Related]
2. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
Fernández-García JC; Colomo N; Tinahones FJ
Med Clin (Barc); 2014 Sep; 143 Suppl 2():18-22. PubMed ID: 25437461
[TBL] [Abstract][Full Text] [Related]
3. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
[TBL] [Abstract][Full Text] [Related]
4. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
Edelman SV
J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
[TBL] [Abstract][Full Text] [Related]
5. Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.
Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Ji L; Zhan S
Endocrine; 2015 Apr; 48(3):794-803. PubMed ID: 25115635
[TBL] [Abstract][Full Text] [Related]
6. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
Camafort-Babkowski M
Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
Nguyen H; Dufour R; Caldwell-Tarr A
Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
[TBL] [Abstract][Full Text] [Related]
8. Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials.
Monami M; Zannoni S; Pala L; Silverii A; Andreozzi F; Sesti G; Mannucci E
Int J Cardiol; 2017 Aug; 240():414-421. PubMed ID: 28501352
[TBL] [Abstract][Full Text] [Related]
9. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Quan X; Ji L; Zhan S
Diabetes Res Clin Pract; 2015 Oct; 110(1):26-37. PubMed ID: 26358202
[TBL] [Abstract][Full Text] [Related]
10. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
Meece J
Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
[TBL] [Abstract][Full Text] [Related]
11. Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists.
Mabilleau G; Pereira M; Chenu C
J Endocrinol; 2018 Jan; 236(1):R29-R42. PubMed ID: 28855317
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
13. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
14. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.
Sun F; Wu S; Wang J; Guo S; Chai S; Yang Z; Li L; Zhang Y; Ji L; Zhan S
Clin Ther; 2015 Jan; 37(1):225-241.e8. PubMed ID: 25554560
[TBL] [Abstract][Full Text] [Related]
15. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
Montvida O; Klein K; Kumar S; Khunti K; Paul SK
Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433
[TBL] [Abstract][Full Text] [Related]
16. Endocrine and metabolic effects of Glucagon like peptide 1 receptor agonists (GLP1RA).
Kalra S; Gupta Y
J Pak Med Assoc; 2016 Mar; 66(3):357-9. PubMed ID: 26968296
[TBL] [Abstract][Full Text] [Related]
17. [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
Consoli A; Di Biagio R
G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):5-9. PubMed ID: 22158421
[TBL] [Abstract][Full Text] [Related]
18. Emerging GLP-1 receptor agonists.
Lund A; Knop FK; Vilsbøll T
Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
[TBL] [Abstract][Full Text] [Related]
19. Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes.
Quast DR; Schenker N; Menge BA; Nauck MA; Kapitza C; Meier JJ
Diabetes Care; 2020 Sep; 43(9):2137-2145. PubMed ID: 32647054
[TBL] [Abstract][Full Text] [Related]
20. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
Meier JJ
Nat Rev Endocrinol; 2012 Dec; 8(12):728-42. PubMed ID: 22945360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]